This is a published notice on the Find a Tender service: https://www.find-tender.service.gov.uk/Notice/022426-2025

Not applicable

Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults)

NHS England

F14: Notice for changes or additional information
Notice identifier: 2025/S 000-022426
Procurement identifier (OCID): ocds-h6vhtk-0515a8
Published 19 May 2025, 8:13am

Section I: Contracting authority/entity

I.1) Name and addresses

NHS England

Wellington House, 133-135 Waterloo Rd

London

SE1 8UG

Contact

Jessica Gaucher-Thompson

Email

jessica.gaucher-thompson@nhs.net

Country

United Kingdom

Region code

UKJ1 - Berkshire, Buckinghamshire and Oxfordshire

Internet address(es)

Main address

https://www.england.nhs.uk/

Buyer's address

https://www.england.nhs.uk/

Section II: Object

II.1) Scope of the procurement

II.1.1) Title

Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults)

II.1.2) Main CPV code

- 85100000 - Health services

II.1.3) Type of contract

Services

II.1.4) Short description

NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England -Specialised Commissioning (referred to as the Authority), is inviting suitably qualified and experienced providers to respond to this Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).

As a result of this procurement exercise an agreement will be established with the successful bidder(s) for a period of three (3) years with the Commissioners having the option to extend for up to an additional two (2) year(s) (maximum contract duration 5 years).

The deadline for submissions is 12.00pm (noon) on Tuesday 24th June 2025.

Section VI. Complementary information

VI.6) Original notice reference

Notice number: 2025/S 000-022156

Section VII. Changes

VII.1.2) Text to be corrected in the original notice

Section number

VI.3.0.1

Instead of

Text

The key objectives of the Procurement are to commission eight (8) Tumour Infiltrating Lymphocyte (TIL) Therapy Hubs for adult patients, for the provision of Lifileucel for previously treated unresectable or metastatic melanoma, across seven (7) geographical lots as outlined below, to serve the population of England. Lot 1: London (2 sites)Lot 2: East of England (1 site)Lot 3: South East (1 site)Lot 4: South West (1 site)Lot 5: Midlands (1 site)Lot 6: North East and Yorkshire (1 site)Lot 7: North West (1 site)Bidders are to note that Providers must be located in and deliver services from the defined geographical area(s) that they are interested in providing services to. Link to NHS England Regions:NHS England » Regional teams (https://www.england.nhs.uk/about/regional-area-teams/). Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a Trust with immediate access to Intensive Therapy Unit (ITU). Lifileucel is being assessed via NICE's technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date of 10th December 2025. Link for the current NICE paperwork:https://www.nice.org.uk/guidance/indevelopment/gid-ta10752Providers are required to be an established site for the delivery of specialist skin cancer care that complies with the requirements as set out in the following specification: https://www.england.nhs.uk/wp-content/uploads/2018/08/Cancer-skin-adult.pdfProviders must also;• Have access to surgical expertise which enables them to perform tumour resections to obtain enough sample tissue for final product to be made. • hold the appropriate Human Tissue Authority licences, which includes having the licence to cover the procurement, donor testing and exporting of the resected tissue.• Have expertise in delivering and managing cellular therapies • Have experience of managing the adverse

effects of interleukin 2 inhibitors. Examples of these adverse events would be those similar to cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome.• Hold a Joint Accreditation Committee of ISCT and EBMT of the European Society for Blood and Marrow Transplantation (JACIE) Immune Effector Cells (IEC) accreditation or be working towards such accreditation. • Be a Heamotopoietic Stem Cell Transplantation centre Providers must be able to meet the requirements set out in this Competitive Process and deliver the contract in accordance with its terms.To express interest and participate in the Competitive Process, please register and apply via Atamis esourcing portal https://health-family.force.com/s/WelcomeShould Tenderers have any queries, or problems using the portal, they should contact the Helpdesk at: Phone: 0800 9956035E-mail: support-health@atamis.co.ukThe closing date for completed Competitive Process responses is 12:00pm (noon), on Tuesday 24th June 2025.Atamis Project reference C41701The contract duration is for three (3) years with the Commissioners having the option to extend for up to an additional two (2) year(s) (maximum contract duration five (5) years).This is a Provider Selection Regime (PSR) Contract Notice. The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply to this award.The decision maker of the award will be: NHS England

Read

Text

The key objectives of the Procurement are to commission eight (8) Tumour Infiltrating Lymphocyte (TIL) Therapy Hubs for adult patients, for the provision of Lifileucel for previously treated unresectable or metastatic melanoma, across seven (7) geographical lots as outlined below, to serve the population of England.Lot 1: London (2 sites)Lot 2: East of England (1 site)Lot 3: South East (1 site)Lot 4: South West (1 site)Lot 5: Midlands (1 site)Lot 6: North East and Yorkshire (1 site)Lot 7: North West (1 site)Bidders are to note that Providers must be located in and deliver services from the defined geographical area(s) that they are interested in providing services to.Link to NHS England Regions:NHS England » Regional teams (https://www.england.nhs.uk/about/regional-area-teams/).Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a Trust with immediate access to Intensive Therapy Unit (ITU).Lifileucel is being assessed via NICE’s technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date of 10th December 2025.Link for the current NICE paperwork:https://www.nice.org.uk/guidance/indevelopment/gid-ta10752Providers are required to be an established site for the delivery of specialist skin cancer care that complies with the requirements as set out in the following specification:

https://www.england.nhs.uk/wp-content/uploads/2018/08/Cancer-skin-adult.pdfProviders must also;• Have access to surgical expertise which enables them to perform tumour resections to obtain enough sample tissue for final product to be made.• hold the appropriate Human Tissue Authority licences, which includes having the licence to cover the procurement, donor testing and exporting of the resected tissue.• Have expertise in delivering and managing cellular therapies• Have experience of managing the adverse effects of interleukin 2 inhibitors. Examples of these adverse events would be those similar to cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome.• Hold a Joint Accreditation Committee of ISCT and EBMT of the European Society for Blood and Marrow Transplantation (JACIE) Immune Effector Cells (IEC) accreditation or be working towards such accreditation.• Be a Heamotopoietic Stem Cell Transplantation centreProviders must be able to meet the requirements set out in this Competitive Process and deliver the contract in accordance with its terms.To express interest and participate in the Competitive Process, please register and apply via Atamis esourcing portal https://health-family.force.com/s/WelcomeShould Tenderers have any queries, or problems using the portal, they should contact the Helpdesk at:Phone: 0800 9956035E-mail: support-health@atamis.co.ukThe closing date for completed Competitive Process responses is 12:00pm (noon), on Tuesday 24th June 2025.Atamis Project reference C341701The contract duration is for three (3) years with the Commissioners having the option to extend for up to an additional two (2) year(s) (maximum contract duration five (5) years).This is a Provider Selection Regime (PSR) Contract Notice. The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply to this award.The decision maker of the award will be: NHS England